Suppr超能文献

[大剂量奥美拉唑与法莫替丁、哌仑西平和抗酸剂治疗急性上消化道出血的回顾性比较]

[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].

作者信息

Busam J, Garbe W E

机构信息

Medizinische Abteilung B, Krankenhaus Rissen, Hamburg.

出版信息

Z Gastroenterol. 1994 Feb;32(2):94-9.

PMID:8165833
Abstract

We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated. The clinical course of AUGIH was evaluated, if emergency endoscopy revealed lesions substantially dependent on intragastric acidity with respect to pathogenesis and/or healing (peptic ulcer, erosive gastroduodenitis, reflux-esophagitis, Mallory-Weiss tears) and patients either received a combined therapy of famotidine (20 mg i.v. every 12 hrs), pirenzepine (10 mg i.v. every 12 hrs) and antacid (control group: n = 96) or omeprazole (40 mg i.v. every 6 hrs; omeprazole group: n = 100). Rate of rebleeding was lower in the omeprazole group without reaching significance (12 vs. 21; p = 0.06). No difference was found for rates of operation (6 vs. 6; p = 0.94), death from bleeding (5 vs. 9; p = 0.22), transfusions ([mean +/- SD] 3.3 +/- 5.0 vs. 3.2 +/- 5.7; p = 0.51) and hospitalisation ([mean +/- SD] 26.8 +/- 12.1 vs. 27.8 +/- 16.0 days; p = 0.88). Considering prognostic risk factors (age > or = 65, actively bleeding lesion, initial state of shock) logistic regression showed that high dose omeprazole inhibited rebleeding (p = 0.01) but had no effect as regards surgery or mortality. Within two selected subgroups defined by additional criteria (no endoscopic treatment and anamnestic peptic lesion) omeprazole-treated cases showed lower rates of rebleeding (3/49 vs. 12/54, p " 0.02 and 3/44 vs. 13/48, p = 0.01 resp.) and death from bleeding (0/46 vs. 6/50, p = 0.03 and 0/43 vs. 5/45, p = 0.03 resp.).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们进行了一项回顾性研究,比较大剂量奥美拉唑与法莫替丁、哌仑西平和抗酸剂联合治疗对急性上消化道出血(AUGIH)的疗效,必要时该联合治疗也作为内镜注射治疗的辅助治疗。如果急诊内镜检查显示病变在发病机制和/或愈合方面(消化性溃疡、糜烂性胃十二指肠炎症、反流性食管炎、马洛里-魏斯撕裂)严重依赖胃内酸度,则对AUGIH的临床病程进行评估,患者要么接受法莫替丁(每12小时静脉注射20毫克)、哌仑西平(每12小时静脉注射10毫克)和抗酸剂的联合治疗(对照组:n = 96),要么接受奥美拉唑(每6小时静脉注射40毫克;奥美拉唑组:n = 100)。奥美拉唑组的再出血率较低,但未达到显著差异(12比21;p = 0.06)。手术率(6比6;p = 0.94)、出血死亡率(5比9;p = 0.22)、输血量([均值±标准差]3.3±5.0比3.2±5.7;p = 0.51)和住院时间([均值±标准差]26.8±12.1比27.8±16.0天;p = 0.88)均无差异。考虑到预后风险因素(年龄≥65岁、活动性出血病变、休克初始状态),逻辑回归显示大剂量奥美拉唑可抑制再出血(p = 0.01),但对手术或死亡率无影响。在根据附加标准定义的两个选定亚组(未进行内镜治疗和有消化性溃疡病史)中,接受奥美拉唑治疗的病例再出血率较低(分别为3/49比12/54,p < 0.02和3/44比13/48,p = 0.01),出血死亡率也较低(分别为0/46比6/50,p = 0.03和0/43比5/45,p = 0.03)。(摘要截断于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验